Semi-automatic Response System(SARS)in Type 2 Diabetes

Sponsor
The Catholic University of Korea (Other)
Overall Status
Completed
CT.gov ID
NCT01058733
Collaborator
(none)
79
1
1
7
11.3

Study Details

Study Description

Brief Summary

Background

  • Various kinds of interactive online communication systems have been introduced for long-term diabetes management, and their importance in managing patients is increasing. The investigators investigated the amount of physician time needed to maintain such a system, and the investigators developed software to maximise the cost effectiveness.

Methods

  • The investigators conducted a prospective, randomised, controlled trial to investigate the efficacy and safety of a semi-automatic response system (SARS) for online glucose monitoring over a 24-week period of patients with type 2 diabetes. In the SARS group, the "SARS" software filtered the recorded self-monitoring of blood glucose data automatically to reduce the physicians' time, and the physicians managed patients regularly but only manually in the control (manual) group. The investigators measured the time spent by the physicians for online management and compared the HbA1c levels at enrolment and follow-up.
Condition or Disease Intervention/Treatment Phase
  • Other: Internet
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
79 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Seoul St. Mary's Hospital College of Medicine The Catholic University of Korea, Seoul, Korea
Study Start Date :
Oct 1, 2006
Actual Primary Completion Date :
May 1, 2007
Actual Study Completion Date :
May 1, 2007

Arms and Interventions

Arm Intervention/Treatment
Other: Internet

New clinical decision-supporting system for glucose monitoring, SARS, which could identify glucose data recorded by patients and make some optimal decisions.The SARS engine assigned subjects to one of three levels according to the glucose control status and glucose control method.

Other: Internet
new clinical decision-supporting system for glucose monitoring, SARS, which could identify glucose data recorded by patients and make some optimal decisions.The SARS engine assigned subjects to one of three levels according to the glucose control status and glucose control method.
Other Names:
  • clinical decision-supporting system
  • Outcome Measures

    Primary Outcome Measures

    1. physicians' labour time and frequency of contact with the online communication system required for reviewing the patients' information and sending recommendations [24 weeks]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    20 Years to 70 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • men or women aged 20-70 years with type 2 diabetes

    • lasting more than one year who had used the online communication system for diabetes management at the web site https://www.bi odang.com for more than six months

    • baseline HbA1c level was 6-10%

    • Patients who able and willing to complete glucose-monitoring diaries on a web chart as instructed.

    Exclusion Criteria:
    • patients who required intensive insulin therapy (multiple insulin injections or insulin pump therapy) or who were unwilling to use self-monitoring of blood glucose (SMBG)

    • acute metabolic complications of diabetes (e.g., diabetic ketoacidosis, hyperosmolar non-ketotic hyperglycaemia, lactic acidosis)

    • serum creatinine concentration >2.0 mg/dl at screening

    • active liver disease or ALT or AST activities >2.5 times the upper limit of normal

    • acute illness, chronic infection, heart failure of NYHA Class III or IV

    • recent myocardial infarction or stroke during the past six months

    • pregnancy or GDM, or any other factor likely to limit protocol compliance or reporting of adverse events

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Seoul St. Mary's Hospital Seoul Korea, Republic of 137-701

    Sponsors and Collaborators

    • The Catholic University of Korea

    Investigators

    • Principal Investigator: Kun-Ho Yoon, Seoul St. Mary's Hospital, Seoul, Korea

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT01058733
    Other Study ID Numbers:
    • SARS-Project
    First Posted:
    Jan 29, 2010
    Last Update Posted:
    Jan 29, 2010
    Last Verified:
    May 1, 2007

    Study Results

    No Results Posted as of Jan 29, 2010